Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. / Zander, Mette; Christiansen, Allan; Madsbad, Sten; Holst, Jens Juul.

In: Diabetes Care, Vol. 27, No. 8, 2004, p. 1910-4.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Zander, M, Christiansen, A, Madsbad, S & Holst, JJ 2004, 'Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.', Diabetes Care, vol. 27, no. 8, pp. 1910-4.

APA

Zander, M., Christiansen, A., Madsbad, S., & Holst, J. J. (2004). Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care, 27(8), 1910-4.

Vancouver

Zander M, Christiansen A, Madsbad S, Holst JJ. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care. 2004;27(8):1910-4.

Author

Zander, Mette ; Christiansen, Allan ; Madsbad, Sten ; Holst, Jens Juul. / Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. In: Diabetes Care. 2004 ; Vol. 27, No. 8. pp. 1910-4.

Bibtex

@article{c82479f0ab5011ddb5e9000ea68e967b,
title = "Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.",
abstract = "OBJECTIVE: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Eight patients with type 2 diabetes (BMI 32.7 +/- 1.3 kg/m(2) and fasting plasma glucose 13.5 +/- 1.2 mmol/l) underwent four different treatment regimens in random order: saline therapy, monotherapy with continuous subcutaneous infusion of GLP-1 (4.8 pmol x kg(-1) x min(-1)), monotherapy with pioglitazone (30-mg tablet of Actos), and combination therapy with GLP-1 and pioglitazone. The observation period was 48 h. End points were plasma levels of glucose, insulin, glucagon, free fatty acids (FFAs), and sensation of appetite. RESULTS: Fasting plasma glucose decreased from 13.5 +/- 1.2 mmol/l (saline) to 11.7 +/- 1.2 (GLP-1) and 11.5 +/- 1.2 (pioglitazone) and further decreased to 9.9 +/- 1.0 (combination) (P < 0.001). Eight-hour mean plasma glucose levels were reduced from 13.7 +/- 1.1 mmol/l (saline) to 10.6 +/- 1.0 (GLP-1) and 12.0 +/- 1.2 (pioglitazone) and were further reduced to 9.5 +/- 0.8 (combination) (P < 0.0001). Insulin levels increased during monotherapy with GLP-1 compared with monotherapy with pioglitazone (P < 0.01). Glucagon levels were reduced in GLP-1 and combination therapy compared with saline and monotherapy with pioglitazone (P < 0.01). FFAs during breakfast (area under the curve, 0-3 h) were reduced in combination therapy compared with saline (P = 0.03). Sensation of appetite was reduced during monotherapy with GLP-1 and combination therapy (P < 0.05). CONCLUSIONS: GLP-1 and pioglitazone show an additive glucose-lowering effect. A combination of the two agents may, therefore, be a valuable therapeutic approach for the treatment of type 2 diabetes.",
author = "Mette Zander and Allan Christiansen and Sten Madsbad and Holst, {Jens Juul}",
note = "Keywords: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors; Thiazolidinediones",
year = "2004",
language = "English",
volume = "27",
pages = "1910--4",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "8",

}

RIS

TY - JOUR

T1 - Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

AU - Zander, Mette

AU - Christiansen, Allan

AU - Madsbad, Sten

AU - Holst, Jens Juul

N1 - Keywords: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors; Thiazolidinediones

PY - 2004

Y1 - 2004

N2 - OBJECTIVE: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Eight patients with type 2 diabetes (BMI 32.7 +/- 1.3 kg/m(2) and fasting plasma glucose 13.5 +/- 1.2 mmol/l) underwent four different treatment regimens in random order: saline therapy, monotherapy with continuous subcutaneous infusion of GLP-1 (4.8 pmol x kg(-1) x min(-1)), monotherapy with pioglitazone (30-mg tablet of Actos), and combination therapy with GLP-1 and pioglitazone. The observation period was 48 h. End points were plasma levels of glucose, insulin, glucagon, free fatty acids (FFAs), and sensation of appetite. RESULTS: Fasting plasma glucose decreased from 13.5 +/- 1.2 mmol/l (saline) to 11.7 +/- 1.2 (GLP-1) and 11.5 +/- 1.2 (pioglitazone) and further decreased to 9.9 +/- 1.0 (combination) (P < 0.001). Eight-hour mean plasma glucose levels were reduced from 13.7 +/- 1.1 mmol/l (saline) to 10.6 +/- 1.0 (GLP-1) and 12.0 +/- 1.2 (pioglitazone) and were further reduced to 9.5 +/- 0.8 (combination) (P < 0.0001). Insulin levels increased during monotherapy with GLP-1 compared with monotherapy with pioglitazone (P < 0.01). Glucagon levels were reduced in GLP-1 and combination therapy compared with saline and monotherapy with pioglitazone (P < 0.01). FFAs during breakfast (area under the curve, 0-3 h) were reduced in combination therapy compared with saline (P = 0.03). Sensation of appetite was reduced during monotherapy with GLP-1 and combination therapy (P < 0.05). CONCLUSIONS: GLP-1 and pioglitazone show an additive glucose-lowering effect. A combination of the two agents may, therefore, be a valuable therapeutic approach for the treatment of type 2 diabetes.

AB - OBJECTIVE: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Eight patients with type 2 diabetes (BMI 32.7 +/- 1.3 kg/m(2) and fasting plasma glucose 13.5 +/- 1.2 mmol/l) underwent four different treatment regimens in random order: saline therapy, monotherapy with continuous subcutaneous infusion of GLP-1 (4.8 pmol x kg(-1) x min(-1)), monotherapy with pioglitazone (30-mg tablet of Actos), and combination therapy with GLP-1 and pioglitazone. The observation period was 48 h. End points were plasma levels of glucose, insulin, glucagon, free fatty acids (FFAs), and sensation of appetite. RESULTS: Fasting plasma glucose decreased from 13.5 +/- 1.2 mmol/l (saline) to 11.7 +/- 1.2 (GLP-1) and 11.5 +/- 1.2 (pioglitazone) and further decreased to 9.9 +/- 1.0 (combination) (P < 0.001). Eight-hour mean plasma glucose levels were reduced from 13.7 +/- 1.1 mmol/l (saline) to 10.6 +/- 1.0 (GLP-1) and 12.0 +/- 1.2 (pioglitazone) and were further reduced to 9.5 +/- 0.8 (combination) (P < 0.0001). Insulin levels increased during monotherapy with GLP-1 compared with monotherapy with pioglitazone (P < 0.01). Glucagon levels were reduced in GLP-1 and combination therapy compared with saline and monotherapy with pioglitazone (P < 0.01). FFAs during breakfast (area under the curve, 0-3 h) were reduced in combination therapy compared with saline (P = 0.03). Sensation of appetite was reduced during monotherapy with GLP-1 and combination therapy (P < 0.05). CONCLUSIONS: GLP-1 and pioglitazone show an additive glucose-lowering effect. A combination of the two agents may, therefore, be a valuable therapeutic approach for the treatment of type 2 diabetes.

M3 - Journal article

C2 - 15277416

VL - 27

SP - 1910

EP - 1914

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 8

ER -

ID: 8418154